Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.
Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Kirste S, Jacobasch L, Allgäuer M, Flentje M, Germer CT, Grützmann R, Hildebrandt G, Schwarzbach M, Bechstein WO, Sülberg H, Friede T, Gaedcke J, Ghadimi M, Hofheinz RD, Rödel C; German Rectal Cancer Study Group.
JAMA Oncol. 2022 Jan 1;8(1):e215445. doi: 10.1001/jamaoncol.2021.5445. Epub 2022 Jan 20.
BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer.
Wang J, Xu Y, Rao X, Zhang R, Tang J, Zhang D, Jie X, Zhu K, Wang X, Xu Y, Zhang S, Dong X, Zhang T, Yang K, Xu S, Meng R, Wu G.
Clin Transl Med. 2022 Jan;12(1):e718. doi: 10.1002/ctm2.718.
Chemoradiotherapy in Cancer Treatment: Rationale and Clinical Applications.
Rallis KS, Lai Yau TH, Sideris M.
Anticancer Res. 2021 Jan;41(1):1-7. doi: 10.21873/anticanres.14746.
Neoadjuvant chemoradiotherapy for resectable oesophageal cancer.
Eyck BM, van der Wilk BJ, Lagarde SM, Wijnhoven BPL, Valkema R, Spaander MCW, Nuyttens JJME, van der Gaast A, van Lanschot JJB.
Best Pract Res Clin Gastroenterol. 2018 Oct-Dec;36-37:37-44. doi: 10.1016/j.bpg.2018.11.007. Epub 2018 Nov 22.
Sub-region based radiomics analysis for survival prediction in oesophageal tumours treated by definitive concurrent chemoradiotherapy.
Xie C, Yang P, Zhang X, Xu L, Wang X, Li X, Zhang L, Xie R, Yang L, Jing Z, Zhang H, Ding L, Kuang Y, Niu T, Wu S.
EBioMedicine. 2019 Jun;44:289-297. doi: 10.1016/j.ebiom.2019.05.023. Epub 2019 May 23.
(Neo)adjuvant Chemoradiotherapy is Beneficial to the Long-term Survival of Locally Advanced Esophageal Squamous Cell Carcinoma: A Network Meta-analysis.
Jin Z, Chen D, Chen M, Wang C, Zhang B, Zhang J, Zhu C, Shen J.
World J Surg. 2022 Jan;46(1):136-146. doi: 10.1007/s00268-021-06301-2. Epub 2021 Sep 5.
[Chemoradiotherapy for pancreatic cancer].
Nakamura S.
Nihon Shokakibyo Gakkai Zasshi. 2015 Dec;112(12):2127-34. doi: 10.11405/nisshoshi.112.2127.
Concurrent chemoradiotherapy using proton beams can reduce cardiopulmonary morbidity in esophageal cancer patients: a systematic review.
Nonaka T, Kawashiro S, Ishikawa H, Ito Y, Nemoto K, Ishihara R, Oyama T, Oyama T, Kato K, Kato H, Kawakubo H, Kawachi H, Kuribayashi S, Kono K, Kojima T, Takeuchi H, Tsushima T, Toh Y, Booka E, Makino T, Matsuda S, Matsubara H, Mano M, Minashi K, Miyazaki T, Muto M, Yamaji T, Yamatsuji T, Yoshida M, Kitagawa Y; Esophageal Cancer Practice Guidelines Preparation Committee.
Esophagus. 2023 Oct;20(4):605-616. doi: 10.1007/s10388-023-01015-x. Epub 2023 Jun 17.
Pancreatic cancer chemoradiotherapy.
Brunner TB, Seufferlein T.
Best Pract Res Clin Gastroenterol. 2016 Aug;30(4):617-28. doi: 10.1016/j.bpg.2016.08.001. Epub 2016 Aug 20.
Definitive chemoradiotherapy for esophageal carcinoma.
Cooper SL, Russo JK, Chin S.
Surg Clin North Am. 2012 Oct;92(5):1213-48. doi: 10.1016/j.suc.2012.07.013.
